In chronic infection, inflammation and cancer, the tissue microenvironment controls how
local immune cells behave, with tissue-resident fibroblasts emerging as a key cell type in …

The acute course of COVID-19 is variable and ranges from asymptomatic infection to
fulminant respiratory failure. Patients recovering from COVID-19 can have persistent …

Tens of thousands of patients with advanced lung diseases may be eligible to be considered
as potential candidates for lung transplant around the world each year. The timing of referral …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Chemo-radiotherapy and systemic therapies have proven satisfactory outcomes as standard
treatments for various thoracic malignancies; however, adverse pulmonary effects, like …

Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide,
reducing their quality of life and leading to death from respiratory failure within years of …

Structural changes involving tissue remodelling and fibrosis are major features of many
pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and …

Summary Background In the Safety and Efficacy of Nintedanib in Systemic Sclerosis
(SENSCIS) trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) in …

Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the
pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel …

Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct
aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and …